🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

18,54 USD

Máx. histórico

178,74

2142 días

Split 1:6 del 12/07/2012

Caída desde máximo

-89,63%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,20%

Cierre anterior

18,32

Rango de hoy

18,29 – 18,81

Volumen hoy

1.397.929

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,44%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 21 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
24/04/2001 32,94 36,60 32,88 35,10 +6,75% 11,29% 39.433
23/04/2001 30,36 33,00 30,00 32,88 +7,45% 9,88% 27.000
20/04/2001 29,70 30,72 29,10 30,60 +3,03% 5,45% 15.583
19/04/2001 29,58 29,88 29,04 29,70 +0,41% 2,84% 10.217
18/04/2001 27,90 29,94 27,90 29,58 +6,25% 7,31% 12.983
17/04/2001 28,80 28,80 26,46 27,84 -7,01% 8,13% 13.683
16/04/2001 26,70 30,90 26,70 29,94 +12,13% 15,73% 11.950
12/04/2001 25,56 26,70 25,20 26,70 +3,49% 5,87% 7.767
11/04/2001 25,50 26,10 25,50 25,80 +1,18% 2,35% 6.600
10/04/2001 24,36 25,50 24,30 25,50 +4,94% 4,93% 8.733
09/04/2001 23,58 24,54 23,40 24,30 +3,68% 4,83% 11.117
06/04/2001 24,19 24,19 23,44 23,44 -4,58% 3,10% 3.850
05/04/2001 23,16 24,56 22,78 24,56 +9,17% 7,69% 6.267
04/04/2001 22,69 24,56 22,50 22,50 +0,00% 9,09% 10.250
03/04/2001 23,44 23,63 21,94 22,50 -4,00% 7,20% 10.933
02/04/2001 24,94 25,13 22,88 23,44 -3,85% 9,02% 7.867
30/03/2001 23,63 24,38 23,44 24,38 +4,00% 3,97% 4.367
29/03/2001 24,75 24,75 23,44 23,44 -5,30% 5,30% 5.767
28/03/2001 25,13 25,97 24,00 24,75 +0,00% 7,84% 5.033
27/03/2001 25,13 25,88 23,63 24,75 -1,49% 8,96% 8.433
26/03/2001 25,13 25,88 23,63 25,13 +6,35% 8,96% 16.767
23/03/2001 23,63 24,00 21,56 23,63 +31,25% 10,32% 52.533
22/03/2001 20,25 21,00 17,44 18,00 -11,11% 17,59% 35.400
21/03/2001 23,06 23,63 20,25 20,25 -12,90% 14,63% 11.267
20/03/2001 24,09 24,19 23,25 23,25 -1,59% 3,89% 13.917
19/03/2001 24,00 25,13 23,44 23,63 -4,55% 7,03% 9.400
16/03/2001 24,94 25,13 24,00 24,75 +1,54% 4,51% 8.283
15/03/2001 24,19 25,88 24,00 24,38 -1,52% 7,75% 8.717
14/03/2001 24,75 25,31 23,25 24,75 -0,75% 8,33% 14.400
13/03/2001 24,00 25,50 23,63 24,94 -2,21% 7,81% 25.850